Upcoming Phase 3 Data in Multiple Myeloma
Nina Shah, MD, discusses some of the important phase 3 trials to emerge from the previous year in multiple myeloma.
EP: 1.Breakthroughs in Therapeutic Options for Relapsed/Refractory Multiple Myeloma
EP: 2.Highlights From the 2021 European Hematology Association Congress on Multiple Myeloma
EP: 3.Upcoming Abstracts on Multiple Myeloma for Presentation at 2021 ASH
EP: 4.Biggest FDA News for Multiple Myeloma in 2021
EP: 5.Treatment Options for Transplant-Eligible Multiple Myeloma
EP: 6.Treatment Options for Transplant-Ineligible Multiple Myeloma
EP: 7.Navigating Individual Treatment for Relapsed/Refractory Multiple Myeloma
EP: 8.Understanding Adverse Events in Multiple Myeloma
EP: 9.BCMA-Directed Agents for Multiple Myeloma
EP: 10.Optimal Therapies for Relapsed/Refractory Multiple Myeloma
EP: 11.Emerging Research and Therapies for Multiple Myeloma
EP: 12.Upcoming Phase 3 Data in Multiple Myeloma
EP: 13.Trials Evaluating Emerging Maintenance Therapy Regimens in Multiple Myeloma
EP: 14.Looking Ahead to the Future of Multiple Myeloma Treatment
EP: 15.Current Leading Therapies for Multiple Myeloma
Nina Shah, MD: There are several ongoing phase 3 trials that I’m hopeful that we’ll see data from. Some of them would include the Perseus trial [NCT03710603], which looks at daratumumab-RVd [lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone] versus RVd with a true primary end point of PFS [progression-free survival]. There are also some Car T-cell [therapy] trials, which are randomizing patients to get Car T-cell therapy versus standard salvage therapy. I’m excited to see what happens there because one of the things we know about myeloma therapy is that using it in later lines might be great but using it in earlier lines almost always is better. Those are the major phase 3 trials I’m looking forward to. We’ve had some readout from randomized phase 2 trials, like the FORTE [NCT02203643] data, which have been very impressive. There are a lot of data coming out with isatuximab [Sarclisa] in the next few years that are going to help us to understand how to best position that drug as well.
